NCT07639528

Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2027-12-10Est. Completion: 2030-12-10

Enrollment target: 44 participants

Locations

Contact

Resectable Intrahepatic Cholangiocarcinoma

This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surge…

Irvine, United StatesEst. completion Feb 12, 2027

Cholangiocarcinoma Non-resectable

This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of hepa…

Wuhan, ChinaEst. completion Jun 30, 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.